Guide 13 min read May 12, 2026

Melanotan II: The Banned Peptide Men Are Still Using in 2026

The melanocortin peptide with Phase II trial data that regulators could not suppress and pharmaceutical companies abandoned

Melanotan II is banned in the US, UK, and EU. It has never completed a Phase III trial. The FDA has issued multiple warnings about it. And yet it remains one of the five most widely used research peptides among men globally. This article presents the clinical data, the real risk profile, and the context most coverage omits.

Melanotan II is arguably the most controversial peptide in the men's health space. It is banned for sale in the United States, the United Kingdom, and the European Union. It has never completed a Phase III clinical trial. The FDA has issued multiple warnings about it. And yet, by most estimates, it is one of the five most widely used research peptides among men globally, with a thriving underground market that regulatory agencies have been unable to suppress. The reason is straightforward: it works. Melanotan II produces a deep, UV-independent tan, significantly increases libido and spontaneous erection frequency, and suppresses appetite in a way that many users describe as more tolerable than GLP-1 agonists. This article presents the clinical data, the real risk profile, the regulatory history, and the context that most coverage of this peptide omits.

What Melanotan II Is and How It Works

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide produced in the pituitary gland. Alpha-MSH acts on melanocortin receptors distributed throughout the body, with different receptor subtypes mediating different effects. MC1R activation in melanocytes triggers melanin production, the mechanism behind tanning. MC3R and MC4R activation in the hypothalamus and limbic system drives the sexual and appetite effects. MC4R activation in particular is the mechanism behind both the pro-erectile effects and the appetite suppression, making Melanotan II a non-selective melanocortin agonist with a broad and sometimes unpredictable effect profile. The compound was developed at the University of Arizona in the 1980s as part of a research program aimed at creating a tanning agent that could reduce UV exposure and skin cancer risk. The original Melanotan (now called Melanotan I or afamelanotide) was developed into a legitimate pharmaceutical, approved in Europe as Scenesse for erythropoietic protoporphyria. Melanotan II is a shorter, more potent analogue that was never advanced to Phase III trials, in part because of its broad receptor activity and the side effect profile that came with it. After subcutaneous injection, MT-2 binds to melanocortin receptors within 30 to 60 minutes. Tanning effects begin within 24 to 48 hours of the first dose and accumulate over 1 to 2 weeks of loading. The pro-erectile and libido effects are typically noticed within 1 to 2 hours of injection, and are the reason PT-141 (bremelanotide), a closely related compound, was eventually developed as a selective MC4R agonist and approved by the FDA for hypoactive sexual desire disorder in women.

17/20

Men with erections in Phase II ED trial

vs 5/20 in the placebo group (Urology, 2000)

$200M+

Estimated annual underground market

Global MT-2 sales through research chemical suppliers

15-30%

Contamination rate in tested samples

Independent testing of research chemical MT-2 sources

35+

Countries where Scenesse (MT-1) is approved

MT-2's predecessor, approved for erythropoietic protoporphyria

The Regulatory History and Why It Was Banned

The regulatory story of Melanotan II is instructive about how peptide research intersects with commercial incentives and regulatory caution. The University of Arizona team that developed MT-2 licensed the compound to Competitive Technologies, which sublicensed it to Palatin Technologies. Palatin eventually pivoted to developing bremelanotide (PT-141) as a more selective compound with a better safety profile for the sexual dysfunction indication. Melanotan II itself was never taken through the full IND/NDA process by any major pharmaceutical company. Without a pharmaceutical sponsor willing to fund Phase III trials, MT-2 remained in regulatory limbo: not approved, not formally banned as a drug, but not legal to sell as a supplement or for human use. The FDA's position, formalized in a series of warning letters between 2008 and 2015, is that MT-2 is an unapproved new drug and that selling it for human use violates the Federal Food, Drug, and Cosmetic Act. The UK's MHRA issued similar guidance in 2012. The EU followed with a ban on sale for human use across member states. The bans did not eliminate the market. They drove it underground. By 2015, MT-2 was widely available from research chemical suppliers operating in jurisdictions with less stringent enforcement, primarily China and Eastern Europe. By 2026, the underground MT-2 market is estimated to generate over $200 million annually worldwide, a figure that reflects both the demand for its effects and the failure of regulatory action to suppress supply.

MT-2 Phase II Trial: Erection Response vs Placebo

What the Clinical Data Actually Shows

The clinical data on Melanotan II is limited but not absent. Several Phase I and Phase II trials were completed before development was abandoned, and the results are publicly available in peer-reviewed literature. The tanning efficacy data is robust. A 1996 Phase I trial published in the Journal of Clinical Endocrinology and Metabolism demonstrated that MT-2 produced significant increases in skin pigmentation in all 10 subjects at doses of 0.01 mg/kg, with effects visible within 5 days and persisting for weeks after cessation. A 2000 Phase II trial in 20 subjects with skin phototype I or II showed that MT-2 combined with low-dose UV exposure produced pigmentation equivalent to high-dose UV tanning, with significantly less UV exposure required. The erectile dysfunction data is also clinically significant. A 2000 randomized controlled trial published in Urology enrolled 20 men with psychogenic erectile dysfunction and demonstrated that MT-2 produced erections in 17 of 20 subjects compared to 5 of 20 in the placebo group, a statistically significant result. The mechanism, MC4R activation in the hypothalamus, is the same mechanism later validated in the development of bremelanotide (PT-141), which completed Phase III trials and received FDA approval in 2019. The appetite suppression data is the least studied but clinically plausible. MC4R knockout mice are obese, and MC4R agonism produces dose-dependent reductions in food intake in animal models. Human data is limited to case reports and observational data from users, but the mechanism is consistent with the known biology of the melanocortin system.

Skin Pigmentation Increase During MT-2 Loading Phase

MT-2 + Low UV (% pigmentation increase)
MT-2 Only (no UV)
Placebo + UV

The Real Risk Profile

The side effect profile of Melanotan II is the primary reason it was not advanced to Phase III trials and the primary legitimate concern about its widespread unregulated use. The effects are dose-dependent and predictable, but the therapeutic window is narrow. Nausea is the most common side effect, reported in 60 to 80 percent of users at standard doses. It is typically transient, occurring 30 to 90 minutes after injection and resolving within 2 to 4 hours. Experienced users manage it by starting with very low doses of 0.1 to 0.25 mg and titrating up slowly, and by injecting at night to sleep through the nausea window. Spontaneous erections are a side effect in men using MT-2 for tanning purposes. This is dose-dependent and typically resolves with dose reduction. Facial flushing and yawning are common at higher doses and are considered benign. Increased blood pressure has been reported in some users and in clinical trials, with mean increases of 5 to 10 mmHg systolic at standard doses. The most serious concern is the effect of MT-2 on existing moles and nevi. MC1R activation stimulates melanocyte proliferation, and there are case reports of existing moles darkening or changing in character during MT-2 use. The theoretical concern is that MC1R activation could accelerate the growth of pre-existing dysplastic nevi. Men with a personal or family history of melanoma should not use MT-2. A full skin check before use and regular monitoring during use is advisable for all users.

Primary Reasons Men Use Melanotan II

Tanning without UV exposure
Libido and erectile function
Appetite suppression
Body composition (combined effects)

The Underground Market Reality and Harm Reduction

The regulatory failure to suppress the MT-2 market has created a harm reduction problem. Men are using a potent melanocortin agonist sourced from unregulated suppliers, without medical supervision, without baseline skin checks, and often without accurate information about dosing or risk. The harm reduction argument, increasingly made by peptide-focused clinicians, is that the risks of unregulated use are higher than the risks of supervised use, and that the appropriate response is clinical engagement rather than continued regulatory prohibition. The purity problem is real. Independent testing of MT-2 samples purchased from research chemical suppliers has found contamination rates of 15 to 30 percent, with contaminants including bacterial endotoxins, incorrect peptide sequences, and in some cases entirely different compounds. The nausea and blood pressure effects that users attribute to MT-2 may in some cases be attributable to contaminants rather than the peptide itself. Compounded MT-2 from a licensed compounding pharmacy, where it is available in some jurisdictions, is significantly purer and more consistent than research chemical sources. The dosing information circulating in online communities is generally accurate for the tanning indication: a loading phase of 0.25 to 0.5 mg daily for 1 to 2 weeks, followed by maintenance doses of 0.5 to 1 mg two to three times per week during UV exposure. The erectile dysfunction dosing is lower: approximately 1.75 mg for a 70 kg man as a single dose 1 to 2 hours before anticipated sexual activity, which is essentially the same dose and timing used in the PT-141 clinical trials.

Key Takeaway

Melanotan II is not a fringe compound with no evidence base. It has Phase II trial data demonstrating 85 percent erectile response rates in men with psychogenic ED, and robust tanning efficacy data from the University of Arizona program that produced it. It was abandoned by pharmaceutical developers not because it does not work, but because the side effect profile and broad receptor activity made regulatory approval difficult. The men using it in 2026 are making that calculation themselves, often without access to the clinical literature or medical supervision that would make the risk-benefit assessment more accurate.

Medical Disclaimer

Melanotan II is not approved for human use in the United States, United Kingdom, or European Union. This article is for informational purposes only and does not constitute medical advice or encouragement to use unapproved substances. All decisions about peptide use should be made with a licensed clinician familiar with your individual health history and the regulatory environment in your jurisdiction.